The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of RVT-3101 in patients with moderate to severely active Crohn’s disease (CD) Roivant recently announced highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results